Xilio Therapeutics Says Repayment In Q1 2024 Of Outstanding Loan Balance Under Xilio's Loan And Security Agreement With Pacific Western Bank, Will Be Sufficient To Fund Its Operating Expenses And Capital Expenditure Requirements Into Q2 2025.
Xilio Therapeutics Says Repayment In Q1 2024 Of Outstanding Loan Balance Under Xilio's Loan And Security Agreement With Pacific Western Bank, Will Be Sufficient To Fund Its Operating Expenses And Capital Expenditure Requirements Into Q2 2025.
Xilio Therapeutics表示，根據Xilio與太平洋西部銀行的貸款和擔保協議，在2024年第一季度償還未償還的貸款餘額，將足以爲其2025年第二季度的運營費用和資本支出需求提供資金。
Xilio Therapeutics Says Repayment In Q1 2024 Of Outstanding Loan Balance Under Xilio's Loan And Security Agreement With Pacific Western Bank, Will Be Sufficient To Fund Its Operating Expenses And Capital Expenditure Requirements Into Q2 2025.
Xilio Therapeutics表示，根據Xilio與太平洋西部銀行的貸款和擔保協議，在2024年第一季度償還未償還的貸款餘額，將足以爲其2025年第二季度的運營費用和資本支出需求提供資金。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。